Tarsus Pharmaceuticals (TARS) Liabilities and Shareholders Equity (2019 - 2026)

Tarsus Pharmaceuticals' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $581.1 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 16.05% year-over-year to $581.1 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 33.23% YoY), while the FY2025 annual figure was $562.2 million, up 49.12% from the prior year.
• Liabilities and Shareholders Equity was $581.1 million for Q1 2026 at Tarsus Pharmaceuticals, up from $562.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $581.1 million in Q1 2026 to a low of $181.5 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $352.1 million across 5 years, with a median of $349.3 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity slipped 25.27% in 2023, then soared 99.47% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $227.9 million in 2022, then grew by 16.51% to $265.5 million in 2023, then surged by 42.0% to $377.0 million in 2024, then jumped by 49.12% to $562.2 million in 2025, then climbed by 3.38% to $581.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $581.1 million (Q1 2026), $562.2 million (Q4 2025), and $534.6 million (Q3 2025), per Business Quant data.